Literature DB >> 19453248

The genetics of Crohn's disease.

Johan Van Limbergen1, David C Wilson, Jack Satsangi.   

Abstract

From epidemiological data, based on concordance data in family studies, via linkage analysis to genome-wide association studies, we and others have accumulated robust evidence implicating more than 30 distinct genomic loci involved in the genetic susceptibility to Crohn's disease (CD). These loci encode genes involved in a number of homeostatic mechanisms: innate pattern recognition receptors (NOD2/CARD15, TLR4, CARD9), the differentiation of Th17-lymphocytes (IL-23R, JAK2, STAT3, CCR6, ICOSLG), autophagy (ATG16L1, IRGM, LRRK2), maintenance of epithelial barrier integrity (IBD5, DLG5, PTGER4, ITLN1, DMBT1, XBP1), and the orchestration of the secondary immune response (HLA-region, TNFSF15/TL1A, IRF5, PTPN2, PTPN22, NKX2-3, IL-12B, IL-18RAP, MST1). While many of these loci also predispose to pediatric CD, an additional number of childhood-onset loci have been identified recently (e.g., TNFRSF6B). Not only has the identification of these loci improved our understanding of the pathophysiology of CD, this knowledge also holds real promise for clinical practice.

Entities:  

Mesh:

Year:  2009        PMID: 19453248     DOI: 10.1146/annurev-genom-082908-150013

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  106 in total

1.  Enteric neuronal density contributes to the severity of intestinal inflammation.

Authors:  Kara Gross Margolis; Korey Stevanovic; Nima Karamooz; Zi Shan Li; Ankur Ahuja; Fabien D'Autréaux; Virginia Saurman; Alcmene Chalazonitis; Michael David Gershon
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

Review 2.  Costimulation of Th17 cells: Adding fuel or putting out the fire in the inflamed gut?

Authors:  Zili Zhang; James T Rosenbaum; Wenwei Zhong; Carmen Lim; David J Hinrichs
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

3.  "ER stress(ed out)!": Paneth cells and ischemia-reperfusion injury of the small intestine.

Authors:  Arthur Kaser; Michal Tomczak; Richard S Blumberg
Journal:  Gastroenterology       Date:  2010-12-18       Impact factor: 22.682

Review 4.  Macrophage-related diseases of the gut: a pathologist's perspective.

Authors:  Xavier Sagaert; Thomas Tousseyn; Gert De Hertogh; Karel Geboes
Journal:  Virchows Arch       Date:  2012-05-11       Impact factor: 4.064

Review 5.  Interplay of autophagy and innate immunity in Crohn's disease: a key immunobiologic feature.

Authors:  Györgyi Műzes; Zsolt Tulassay; Ferenc Sipos
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

6.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.

Authors:  Nigel Ramsden; Jessica Perrin; Zhao Ren; Byoung Dae Lee; Nico Zinn; Valina L Dawson; Danny Tam; Michael Bova; Manja Lang; Gerard Drewes; Marcus Bantscheff; Frederique Bard; Ted M Dawson; Carsten Hopf
Journal:  ACS Chem Biol       Date:  2011-08-10       Impact factor: 5.100

7.  NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients.

Authors:  Nora Meggyesi; Lajos S Kiss; Magdalena Koszarska; Martin Bortlik; Dana Duricova; Laszlo Lakatos; Tamas Molnar; Martin Leniček; Libor Vítek; Istvan Altorjay; Maria Papp; Zsolt Tulassay; Pal Miheller; Janos Papp; Attila Tordai; Hajnalka Andrikovics; Milan Lukas; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

8.  Charting a course for genomic medicine from base pairs to bedside.

Authors:  Eric D Green; Mark S Guyer
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

Review 9.  Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.

Authors:  Altin Gjymishka; Roxana M Coman; Todd M Brusko; Sarah C Glover
Journal:  Immunotherapy       Date:  2013-12       Impact factor: 4.196

10.  Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection.

Authors:  N Nazareth; F Magro; J Silva; M Duro; D Gracio; R Coelho; R Appelberg; G Macedo; A Sarmento
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.